SULFAPYRIDINE Drug Patent Profile
✉ Email this page to a colleague
When do Sulfapyridine patents expire, and when can generic versions of Sulfapyridine launch?
Sulfapyridine is a drug marketed by Lilly and is included in one NDA.
The generic ingredient in SULFAPYRIDINE is sulfapyridine. There are seven drug master file entries for this compound. Additional details are available on the sulfapyridine profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for SULFAPYRIDINE?
- What are the global sales for SULFAPYRIDINE?
- What is Average Wholesale Price for SULFAPYRIDINE?
Summary for SULFAPYRIDINE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 117 |
| Clinical Trials: | 1 |
| Patent Applications: | 3,240 |
| DailyMed Link: | SULFAPYRIDINE at DailyMed |
Recent Clinical Trials for SULFAPYRIDINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Assistance Publique - Hôpitaux de Paris | Phase 1/Phase 2 |
Medical Subject Heading (MeSH) Categories for SULFAPYRIDINE
Anatomical Therapeutic Chemical (ATC) Classes for SULFAPYRIDINE
US Patents and Regulatory Information for SULFAPYRIDINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lilly | SULFAPYRIDINE | sulfapyridine | TABLET;ORAL | 000159-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
